Burrill: FDA's 2011 approval rate can't mask underlying problems; Forest campaigns for support as Icahn closes in;

@FierceBiotech: BDO: Biotechs continue to rein in R&D costs, focus on top prospects. Piece | Follow @FierceBiotech

@JohnCFierce: RNAi just keeps getting colder. | Follow @JohnCFierce

@RyanMFierce: Sequencing giant BGI shoots for the cloud, look out Complete Genomics? Article | Follow @RyanMFierce

@MaureenFierce: Big Pharma's cutbacks are small biotechs' opportunity. Story via Seeking Alpha | Follow @MaureenFierce

> Biotech analyst Steven Burrill notes that the FDA has now approved 21 new drugs so far this year, a match for all of 2010. But he adds that the underlying problems afflicting development still need to be resolved. "The industry has to reverse a long-term decline in R&D productivity. And the FDA has to find a way to ensure the safety of new drugs while not slowing the introduction of new and needed therapies or creating undue burdens for developers." Release

> Fighting off an assault by activist investor Carl Icahn, Forest Labs says that it is well positioned for growth as it urged investors to back its slate of board candidates and reject the rebel band backed by Icahn. Report

> The FDA has approved a subcutaneous formula for the RA drug Orencia. Story

Pharma News

@FiercePharma: Pfizer nutritionals unit on deck for auction. Could be a $10.5B deal. Item | Follow @FiercePharma

> Shionogi strikes a deal for China's C&O Pharma. Story

> Forest lambastes Ichan in proxy-fight letter. Report

Biotech IT News

> A free app to bypass Myriad's gene patent: How can gaming aid life science researchers? Item

> Survey: Developers stumble when projecting trial costs. Piece

> Sequencing giant BGI shoots for the cloud. More

> FDA eys "value" of modeling used in drug development. News

> Ontario cancer group to get $40M deal, expand bioinformatics effort. Article

> PharmaPros teams up with Soltex, etends pharma reach. Story

> Eying big pharma needs, Icon xplains clinical tech buyout. Report

Medical Devices News

> CR Bard CFO to retire. Piece

> FDA Oks Medtronic study of second-generation pacing system. More

> World Heart to stop Levacore deelopment, reduce workforce. News

> Baxter establishs $200M venture arm. Report

> Boston Scientific to cut 1,400 jobs. Story

> Intuity closes $76M Series D financing. Article

> IOM report fuels debate over device reviews. More

And Finally... Slightly more than a third of the patients taking opioids for chronic pain qualify as addicts. Report

Suggested Articles

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.

The takeover will give Orgenesis control of an autologous cell therapy treatment for respiratory disease caused by COVID-19.